Drug intelligence / Profile preview

CB-0406

Development stage: Phase 1
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Oral

Overview

CB-0406 is an orally administered small molecule drug that was developed by CymaBay Therapeutics (a subsidiary of Gilead Sciences) as a peroxisome proliferator-activated receptor gamma (PPARγ) agonist. It was investigated primarily for its anti-inflammatory and hepatoprotective properties, with a focus on indications such as non-alcoholic steatohepatitis (NASH) and inflammation. The drug reached Phase 1 clinical trials in healthy volunteers but development was discontinued due to safety concerns. There are no approved indications or orphan designations for this compound.

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)

Beyond the preview

Go deeper on CB-0406.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB-0406.

Explore the full profile